| Literature DB >> 27035874 |
Ankit Sharma1, Madankumar Ghatge1, Lakshmi Mundkur2, Rajani Kanth Vangala1.
Abstract
Translational informatics approaches are required for the integration of diverse and accumulating data to enable the administration of effective translational medicine specifically in complex diseases such as coronary artery disease (CAD). In the current study, a novel approach for elucidating the association between infection, inflammation and CAD was used. Genes for CAD were collected from the CAD‑gene database and those for infection and inflammation were collected from the UniProt database. The cytomegalovirus (CMV)‑induced genes were identified from the literature and the CAD‑associated clinical phenotypes were obtained from the Unified Medical Language System. A total of 55 gene ontologies (GO) termed functional communicator ontologies were identified in the gene sets linking clinical phenotypes in the diseasome network. The network topology analysis suggested that important functions including viral entry, cell adhesion, apoptosis, inflammatory and immune responses networked with clinical phenotypes. Microarray data was extracted from the Gene Expression Omnibus (dataset: GSE48060) for highly networked disease myocardial infarction. Further analysis of differentially expressed genes and their GO terms suggested that CMV infection may trigger a xenobiotic response, oxidative stress, inflammation and immune modulation. Notably, the current study identified γ‑glutamyl transferase (GGT)‑5 as a potential biomarker with an odds ratio of 1.947, which increased to 2.561 following the addition of CMV and CMV‑neutralizing antibody (CMV‑NA) titers. The C‑statistics increased from 0.530 for conventional risk factors (CRFs) to 0.711 for GGT in combination with the above mentioned infections and CRFs. Therefore, the translational informatics approach used in the current study identified a potential molecular mechanism for CMV infection in CAD, and a potential biomarker for risk prediction.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27035874 PMCID: PMC4838147 DOI: 10.3892/mmr.2016.5013
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Figure 1Methodology for identifying important pathways and associated biomarkers linking CAD, infection and infammation. CAD, coronary artery disease; HCMV, human cytomegalovirus; UMLS, Unified Medical Language System.
The 34 medical terms associated with coronary artery disease extracted from the Unified Medical Language System.
| Medical term |
|---|
| 1. Tobacco abuse |
| 2. Angina |
| 3. Exercise stress test abnormal |
| 4. Chest pain |
| 5. Shortness of breath |
| 6. Obesity |
| 7. Coronary artery disease risk high |
| 8. Hypertension |
| 9. Coronary artery bypass graft |
| 10 Organic heart disease |
| 11. Heart |
| 12. Angina stable |
| 13. Epigastric pain |
| 14. Myocardial infarction acute |
| 15. Angina unstable |
| 16. Orthopnea |
| 17. Coronary atherosclerotic heart disease |
| 18. Cardiac arrest |
| 19. Diabetic retinopathy |
| 20. Lower extremity edema |
| 21. Congestive heart failure |
| 22. Myocardial infarction |
| 23. Cardiac catheterization |
| 24. Electrocardiogram abnormal |
| 25. Percutaneous transluminal coronary angioplasty planned |
| 26. Pyuria |
| 27. Hypercholesterolemia |
| 28. Diabetes mellitus |
| 29. Atrial fibrillation new onset |
| 30. Ischemic heart disease silent |
| 31. Weight loss |
| 32. Diabetes mellitus insulin dependent |
| 33. Dyspnea paroxysmal nocturnal |
| 34. Hyperlipidemia |
Did not elicit any hits in the UniProt database.
Number of genes, their ontologies and identified FCOs linking molecular data and clinical phenotypes.
| Category | No. of genes | No. of gene ontology terms | No. of common ontologies | No. of parent FCOs |
|---|---|---|---|---|
| Coronary artery disease | 604 | 4277 | 783 | 55 |
| Infection | 475 | 2556 | ||
| Inflammation | 814 | 4525 | ||
| Cytomegalovirus | 433 | 2263 | ||
| UMLS (medical ontologies) | 3489 | 8284 |
FCOs, functional communicator ontologies; UMLS, unified Medical Language System.
Figure 2Network of 55 FCOs and 23 clinical phenotypes. The nodes indicate the FCOs and clinical phenotypes for coronary artery disease, and the edges indicate the associations between FCOs and clinical phenotypes. FCOs, functional communicator ontologies; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MAPKKK, MAPK kinase kinase; JAK, Janus kinase; STAT, signal transducer and activation of transcription; NF, nuclear factor.
Highly connected functional communicator ontologies based on node degree distribution and average short path in the network.
| Gene ontology term | Average short path | Node degree |
|---|---|---|
| Apoptosis | 1.86440678 | 14 |
| Cell adhesion | 1.93220339 | 12 |
| Mitochondrion | 1.96610169 | 11 |
| Regulation of apoptosis | 2 | 10 |
| Cytokine activity, endocytosis | 2.06779661 | 8 |
| Lipid metabolism, stress-activated MAPK cascade, endosome, carbohydrate metabolism, immune response | 2.10169492 | 7 |
| Lysosome | 2.13559322 | 6 |
| Viral life cycle, stress response, MAPKKK cascade | 2.16949153 | 5 |
| Entry of virus into host cell | 2.20338983 | 4 |
| Response to external stimulus, B cell activation, induction of apoptosis via death domain receptors, entry into host cell, phosphoinositide 3-kinase cascade | 2.23728814 | 3 |
| Regulation of c-Jun N-terminal kinase cascade | 2.20338983 | 4 |
| Complement activation-classical pathway, hormone secretion, phagocytosis, cytokine production, T cell activation, cytokine secretion, Janus kinase-signal transducer and activator of transcription cascade | 2.27118644 | 2 |
| Complement activation, cytokine biosynthesis, humoral defense mechanism & immune response, protein metabolism, regulation of I-κB kinase/NF-κB cascade, regulation of MAPKKK cascade, response to biotic stimulus | 2.30508475 | 1 |
MAPK, mitogen-activated protein kinase; MAPKKK, MAPK kinase kinase.
Top 5 highly networked clinical terminologies based on node degree distribution.
| Name | Average short path | Node degree (functional communicator ontologies) |
|---|---|---|
| MI including acute MI | 2.52542373 | 14 (entry of virus into host cell, endosome, apoptosis, regulation of apoptosis, stress-activated MAPK cascade, stress response, immune response, immunity, cell adhesion, endocytosis, apoptosis via death domain receptors, inflammation, regulation of infammation, external side of membrane) |
| Cardiac arrest | 2.37288136 | 10 (viral life cycle, cell adhesion, stress response, apoptosis, regulation of apoptosis, cytokine activity, immune response, mitochondrion, carbohydrate metabolism, stress-activated MAPK cascade) |
| Congestive heart failure | 2.47457627 | 7 (cell adhesion, apoptosis, regulation of apoptosis, apoptosis by death domain receptors, mitochondrion, stress-activated MAPK cascade, lysosome) |
| Chest pain | 2.6779661 | 3 (cell adhesion, apoptosis, mitochondrion) |
| Angina | 2.98305085 | 1 (regulation of apoptosis) |
MI, myocardial infarction; MAPK, mitogen-activated protein kinase.
Figure 3(A) Common GO terms from global gene expression analysis and 78 GO terms. (B) Potential molecular mechanism of the association between infection, inflammation and coronary artery disease. GO, gene ontology.
Base line characteristics of patient group selected for study.
| Variables | Unaffected (n=200) | Affected (MI, n=200) | P-value |
|---|---|---|---|
| Age | 51.88±0.74 | 51.90±0.74 | 0.98 |
| Gender (Male) | 157 (78.5%) | 157 (78.5%) | 0.548 |
| Gender (Female) | 43 (21.5%) | 43 (21.5%) | |
| Body mass index kg/m2 | 25.21±0.284 | 25.69±0.280 | 0.22 |
| Waist:hip ratio | 0.93±0.005 | 0.94±0.005 | 0.28 |
| Waist circumference | 90.61±0.73 | 90.35±0.85 | 0.81 |
| Total cholesterol | 177.41±2.83 | 150.49±2.64 | 1.54 |
| Triglycerides | 160.71±7.716 | 159.44±5.10 | 0.89 |
| High-density lipoprotein | 37.58±0.66 | 35.29±0.60 | 0.011 |
| Low-density lipoprotein | 110.47±2.53 | 83.30±2.35 | 3.85 |
| Smoking, n (%) | 58 (29.0%) | 94 (47.0%) | 1.49 |
| Alcohol consumption, n (%) | 42 (21.0%) | 27 (13.5%) | 0.032 |
| Hypertension, n (%) | 50 (25.0%) | 82 (41.0%) | 4.72 |
| Diabetes mellitus, n (%) | 48 (24.0%) | 88 (44.0%) | 1.76 |
| Statin, n (%) | 8 (4.0%) | 137 (68.5%) | 1.88 |
| Beta blocker, n (%) | 26 (13.0%) | 124 (62.0%) | 2.68 |
| Fibrate, n (%) | 1 (0.5%) | 8 (4.0%) | 0.018 |
| Calcium channel blocker, n (%) | 20 (10.0%) | 51 (25.5%) | 1.40 |
| ACE inhibitor, n (%) | 15 (7.5%) | 87 (43.5%) | 1.40 |
| Hypoglycemic agents, n (%) | 38 (19.0%) | 63 (31.5%) | 0.003 |
| Nitrate, n (%) | 1 (0.5%) | 86 (43.0%) | 7.09 |
| Antiplatelet, n (%) | 7 (3.5%) | 177 (88.5%) | 1.24 |
| Biomarkers | |||
| GGT | 32.05±0.97 | 36.05±1.25 | 0.011 |
| CMV | 9.69±0.514 | 12.55±0.66 | 0.001 |
| CMV-NA titres | 4.67±0.052 | 4.92±0.074 | 0.008 |
Mean ± standard error;
Log-transformed mean ± standard error (retransformed mean). Significance was determined by Student's t-test for variables expressed as the mean ± standard error and by the χ2 test for variables expressed as percentages. CMV data previously presented (8). MI, myocardial infarction; ACE, angiotensin-converting enzyme; GGT, γ-glutamyl transpeptidase; CMV, cytomegalovirus; CMV-NA, CMV-neutralizing antibody.
Logistical regression analysis for the association between GGT-5 and myocardial infarction in combination with CMV infection markers.
| Model | Odds ratio (95% CI) | AUC (95% CI) |
|---|---|---|
| CRFs | – | 0.530 (0.47–0.58) |
| CMV | 1.31 (1.04–1.63) | 0.593 (0.53–0.65) |
| CMV-NA titres | 1.457 (1.10–1.92) | 0.587 (0.52–0.65) |
| GGT | 1.947 (1.14–3.310) | 0.570 (0.51–0.62) |
| GGT + CMV-NA titres | 1.872 (1.03–3.41) | 0.604 (0.54–0.67) |
| GGT + CMV | 2.226 (1.26–3.92) | 0.620 (0.56–0.67) |
| GGT + CMV-NA titres + CMV | 2.133 (1.12–4.03) | 0.633 (0.57–0.69) |
| GGT + CMV-NA titres + CMV + CRFs + lipids | 2.338 (1.17–4.64) | 0.704 (0.64–0.76) |
| GGT + CMV-NA titres + CMV + CRFs + lipids + alcohol consumption | 2.561 (1.27–5.15) | 0.711 (0.64–0.77) |
P<0.001,
P<0.01,
P<0.05,
P>0.05. CRFs include waist circumference, hypertension, diabetes and smoking. The Hosmer lemshow test was performed for all the models and those with P<0.05 are reported here. CMV data previously presented (8). GGT, γ-glutamyl transpeptidase; CMV, cytomegalovirus; CI, confidence interval; AUC, area under the curve; CRFs, conventional risk factors; CMV-NA, CMV-neutralizing antibody.